New Delhi, Feb 28 (IANS) Scientists at the Christian Medical College (CMC) Vellore have successfully conducted the country’s first human clinical trial of gene therapy for haemophilia A (FVIII deficiency), Union Minister Dr. Jitendra Singh said on Wednesday. He said this while addressing the “National Science Day 2024” programme at Vigyan Bhawan here.
Hemophilia A is a genetic disorder caused by missing or defective factor VIII (FVIII), a clotting protein, which means the patient bleeds longer than others.
The clinical trials involved deploying a novel technology of using a lentiviral vector to express a FVIII transgene in the patient’s own haematopoietic stem cell, which will then express FVIII from specific differentiated blood cells.
India is home to the second-largest population of patients living with Haemophilia, with an estimated 1,36,000 individuals grappling with hemophilia A.
However, only around 21,000 are registered at present.
About 80 per cent of hemophilia cases go undiagnosed in India as several hospitals and medical institutions lack screening capabilities for blood clotting, affecting the diagnosis of new cases. “The manufacturing of this vector will commence soon in India and proceed with further clinical trials,” the minister said.
The trial was supported by the Department of Biotechnology, the Centre for Stem Cell Research — a unit of InStem Bengaluru, in collaboration with Emory University, US at Christian Medical College, Vellore.
In about 80 per cent cases, haemophilia manifests as bleeding, most frequently involving the large joints like knees, ankles, elbows, hip and wrist, followed by deep bleeds affecting large body muscles.
However, the most dangerous ones are bleeds affecting the head/brain, neck, chest cavity and abdominal and pelvic cavity.
–IANS
rvt/pgh
Disclaimer
The information contained in this website is for general information purposes only. The information is provided by TodayIndia.news and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
In no event will we be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from loss of data or profits arising out of, or in connection with, the use of this website.
Through this website you are able to link to other websites which are not under the control of TodayIndia.news We have no control over the nature, content and availability of those sites. The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.
Every effort is made to keep the website up and running smoothly. However, TodayIndia.news takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.
For any legal details or query please visit original source link given with news or click on Go to Source.
Our translation service aims to offer the most accurate translation possible and we rarely experience any issues with news post. However, as the translation is carried out by third part tool there is a possibility for error to cause the occasional inaccuracy. We therefore require you to accept this disclaimer before confirming any translation news with us.
If you are not willing to accept this disclaimer then we recommend reading news post in its original language.
